Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study

References

• AttardGParkerCEelesRAProstate cancerLancet201638710013708226074382
   PubMed Web of Science ®Google Scholar
• CenterMMJemalALortet-TieulentJInternational variation in prostate cancer incidence and mortality ratesEur Urol20126161079109222424666
   PubMed Web of Science ®Google Scholar
• CarteniGPappagalloGCarcinoma della prostata resistente alla castrazione in Italia: un unmet medical need in via di risoluzione. [Castrate resistant prostate cancer in Italy: an unmet medical need about to be solved]Ital J Public Health20118Suppl 4S3S8 Italian
   Google Scholar
• AIOMAIRTUMCCMI numeri del cancro in Italia 2015. [The numbers of cancer in Italy 2015] Available http://www.registri-tumori.it/PDF/AIOM2015/I_numeri_del_cancro_2015.pdfAccessed November 10, 2017
   Google Scholar
• ZarifJCMirantiCKThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceCell Signal201628534835626829214
   PubMed Web of Science ®Google Scholar
• GillessenSAttardGBeerTMManagement of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017Eur Urol Epub2017624
   Web of Science ®Google Scholar
• MostaghelEAPageSTLinDWIntraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancerCancer Res200767105033504117510436
   PubMed Web of Science ®Google Scholar
• RitchCRCooksonMSAdvances in the management of castration resistant prostate cancerBMJ2016355i440527754846
   PubMed Web of Science ®Google Scholar
• LorenteDFizaziKSweeneyCde BonoJSOptimal treatment sequence for metastatic castration-resistant prostate cancerEur Urol Focus20162548849828723514
   PubMedGoogle Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• BahlAOudardSTombalBImpact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trialAnn Oncol20132492402240823723295
   PubMed Web of Science ®Google Scholar
• HeidenreichAScholzHJRogenhoferSCabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programmeEur Urol201363697798223116658
   PubMed Web of Science ®Google Scholar
• de BonoJHardy-BessardA-CKimC-SPhase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D) [Abstract]J Clin Oncol20163415 Suppl5008
   Web of Science ®Google Scholar
• OudardSFizaziKSengelovLCabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANAJ Clin Oncol2017 JCO2016721068
   PubMed Web of Science ®Google Scholar
• YapTACardenCPAttardGde BonoJSTargeting CYP17: established and novel approaches in prostate cancerCurr Opin Pharmacol20088444945718619560
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMolinaAAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol2012131098399222995653
   PubMed Web of Science ®Google Scholar
• LogothetisCJBaschEMolinaAEffect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialLancet Oncol201213121210121723142059
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• BeerTMArmstrongAJRathkopfDEEnzalutamide in metastatic prostate cancer before chemotherapyN Engl J Med2014371542443324881730
   PubMed Web of Science ®Google Scholar
• HenriksenGBreistolKBrulandOSFodstadOLarsenRHSignificant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases modelCancer Res200262113120312512036923
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• SartorOColemanRNilssonSEffect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialLancet Oncol201415773874624836273
   PubMed Web of Science ®Google Scholar
• HoskinPSartorOO’SullivanJMEfficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialLancet Oncol201415121397140625439694
   PubMed Web of Science ®Google Scholar
• NilssonSCisloPSartorOPatient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA studyAnn Oncol201627586887426912557
   PubMed Web of Science ®Google Scholar
• SaadFCarlesJGillessenSRadium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialLancet Oncol20161791306131627473888
   PubMed Web of Science ®Google Scholar
• BodyJJCasimiroSCostaLTargeting bone metastases in prostate cancer: improving clinical outcomeNat Rev Urol201512634035626119830
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• AIOM – Associazione Italiana di Oncologia Medica. APP Linee Guida 2014: Carcinoma della prostata. 2015. [AIOM - Italian Association of Medical Oncology. APP Guidelines 2014: Prostate cancer. 2015] Available from: http://www.aiom.it/Accessed November 10, 2017
   Google Scholar
• HeidenreichABastianPJBellmuntJEAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol201465246747924321502
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate CancerNational Comprehensive Cancer Network (NCCN)2015
   Google Scholar
• EvangelistaLBertoldoFBoccardoFDiagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizonsEur J Nucl Med Mol Imaging20164381546156226956538
   PubMed Web of Science ®Google Scholar
• DragomirADineaDVanhuyseMCuryFLAprikianAGDrug costs in the management of metastatic castration-resistant prostate cancer in CanadaBMC Health Serv Res20141425224927758
   PubMed Web of Science ®Google Scholar
• MolinierLBauvinECombescureCMethodological considerations in cost of prostate cancer studies: a systematic reviewValue Health200811587888518494749
   PubMed Web of Science ®Google Scholar
• AkobunduEJuJBlattLMullinsCDCost-of-illness studies: a review of current methodsPharmacoeconomics200624986989016942122
   PubMed Web of Science ®Google Scholar
• MarcellusiAVitiRMecozziAMenniniFSThe direct and indirect cost of diabetes in Italy: a prevalence probabilistic approachEur J Health Econ201617213914725427540
   PubMed Web of Science ®Google Scholar
• HechmatiGCureSGouépoACost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational studyJ Med Econ201316569170023441975
   PubMedGoogle Scholar
• International Monetary FundWorld Economic Outlook Database – April 2017 Available from: http://www.imf.org/external/pubs/ft/weo/2017/01/weodata/index.aspxAccessed November 10, 2017
   Google Scholar
• EUROSTATEuro/ECU Exchange Rates – Annual Data Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=ert_bil_eur_a&lang=en2017Accessed November 10, 2017
   Google Scholar
• FourcadeROBenedictABlackLKStokesMEAlcarazACastroRTreatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UKBJU Int20101051495620132102
   PubMed Web of Science ®Google Scholar
• ParkerCZhanLCisloPReuning-SchererJEffect of radium-233 dichloride (Ra-223) on hospitalization and its economic implications in ALSYMPCA trial [Abstract 1230]Eur J Cancer201551SupplS183
   Web of Science ®Google Scholar
• VerzoniETucciMCaruggiMColomboGLRadio-223 dicloruro nel trattamento del carcinoma metastatico della prostata resistente alla castrazione: un’analisi di Budget Impact per il Servizio Sanitario Nazionale. [Radium-223 dichloride for the treatment of metastatic Castrate Resistant Prostate Cancer: a budget impact analysis for the Italian National Health Service]ClinicoEconomics2016112944 Italian
   Google Scholar
• RestelliUTucciMCroceDImpatto economico di Radio-223 nel trattamento del tumore della prostata metastatico resistente alla castrazione (mCRPC), 2016. In “Radio-223 nel trattamento del carcinoma della prostata metastatico resistente alla castrazione (mCRPC): risultati di una valutazione di Health Technology Assessment”. [Economic impact of Radium-223 for the treatment of metastatic castrate resistant prostate cancer (mCRPC), 2016. In “Radium-223 for the treatment of metastatic castrate resistant prostate cancer (mCRPC): Health Technology Assessment results] Available from: http://www.ijph.it/pdf/2016-v5-n7.pdfAccessed November 10, 2017
   Google Scholar
• RathkopfDESmithMRde BonoJSUpdated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Eur Urol201466581582524647231
   PubMed Web of Science ®Google Scholar
• HorganAMSerugaBPondGRTolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trialJ Geriatr Oncol20145211912624495703
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMillerKEffect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialLancet Oncol201415101147115625104109
   PubMed Web of Science ®Google Scholar
• ParkerCZhanLCisloPEffect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trialEur J Cancer2017711627930924
   PubMed Web of Science ®Google Scholar
• Regione del Veneto, Giunta Regionale. Allegato A al Decreto n. 125 del 14 novembre 2016. [Veneto Region, Regional Commettee, Annex A to the Decree 125 - 14 November 2016] Available from: http://www.regione.veneto.it/c/document_library/get_file?uuid=8cbaf3b9-6a7f-405b-8a9f-392327563208&groupId=10793Accessed November 10, 2017
   Google Scholar
• Regione del Veneto, Giunta Regionale. Allegato B al Decreto n. 291 del 7 ottobre 2015. [Veneto Region, Regional Commettee, Annex B to the Decree 291 - 7 October 2015] Available from: bur.regione.veneto.it/BurvServices/Pubblica/Download.aspx?name=291_Allegato_B_DDR_291_07-10-2015_308781.pdf&type=7&storico=FalseAccessed November 10, 2017
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 2 agosto 2013. Rine-goziazione del medicinale per uso umano «Prolia», ai sensi dell’art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina 732/2013) (Gazzetta n. 194 del 20 agosto 2013). [Italian Medicines Agency. Resolution 2 August 2013. Renegotiation of the human medicine “Prolia”, in accordance with article 8, comma 10, of the law of 24 December 1993, n. 537. (Resolution n. 732/2013) (Gazette n. 194 - 20 August 2013)] Available from: http://www.gazzettaufficiale.it/eli/id/2013/08/20/13A06863/sgAccessed November 10, 2017
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 7 marzo 2016. Autorizzazione all’immissione in commercio del medicinale per uso umano «Acido Zoledronico Sun Pharma» (Determina n. 732/2016) (Gazzetta no. 70 del 24 marzo 2016). [Italian Medicines Agency. Resolution 7 March 2016. Marketing authorisation of the human medicine “Acido Zoledronico Sun Pharma” (Resolution n. 732/2016) (Gazette n. 70 - 24 March 2016)] Available from: http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario;jsessionid=WMHMtgUOYHLyIvdYvhNMnA__ntc-as3-guri2a?atto.dataPubblicazioneGazzetta=2016-03-24&atto.codiceRedazionale=16A02346&elenco30giorni=falseAccessed November 10, 2017
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 31 luglio 2012. Procedure di payback – anno 2012 (Gazzetta n. 183 del 17 agosto 2012). [Italian Medicines Agency. Resolution 31 July 2012. Payback procedures - year 2012 (Gazette n. 283 - 17 August 2012)] Available from: www.gazzettauf-ficiale.it/eli/gu/2012/08/07/183/sg/pdfAccessed November 10, 2017
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 1 agosto 2013. Classificazione del medicinale per uso umano «Enantone», ai sensi dell’art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 715/2013) (Gazzetta n. 194 del 20 agosto 2013). [Italian Medicines Agency. Resolution 1 August 2013. Classification of the human medicine “Enantone”, in accordance with article 8, comma 10, of the law of 24 December 1993, n. 537. (Resolution n. 715/2013) (Gazette n. 194 - 20 August 2013)] Available from: http://www.gazzettauf-ficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2013-08-20&atto.codiceRedazionale=13A06866&elenco30giorni=falseAccessed November 10, 2017
   Google Scholar
• Agenzia Italiana del Farmaco. Comunicato. Determinazioni di rimborsabilità e prezzo di vendita, autorizzazioni, modificazioni e rettifiche all’immissione in commercio di vari medicinali (Gazzetta n. 271 del 21 novembre 2007 suppl. ordinario n. 239). [Italian Medicines Agency. Pubblic announcement. Resolution on reimbursement and selling price, authorizations, modifications and amendments to the marketing authorization of various medicines (Gazette n. 271 - 21 November 2007 ordinary supplement n. 239)] Available from: http://www.gazzettauf-ficiale.it/eli/id/2007/11/21/07A09472/sgAccessed November 10, 2017
   Google Scholar
• Agenzia Italiana del Farmaco. Determinazione 11 aprile 2011. Regime di rimborsabilità e prezzo di vendita del medicinale «Firmagon» (degarelix). (Determinazione/C n. 2168/2011) (Gazzetta n. 92 del 21 aprile 2011). [Italian Medicines Agency. Resolution 11 April 2011. Reimbursement regime and selling price of the medicine “Firmagon” (degarelix). (Resolution/C n. 2168/2011) (Gazette n. 92 - 21 April 2011)] Available from: http://www.gazzettaufficiale.it/eli/id/2011/04/21/11A04989/sgAccessed November 10, 2017
   Google Scholar
• GeraceCMontorsiFTambaroRCost of illness of urothelial bladder cancer in ItalyClinicoecon Outcomes Res2017943344228769578
   PubMed Web of Science ®Google Scholar